Open Access<p>HLJ2 Effectively Ameliorates Colitis-Associated Cancer via Inhibition of NF-κB and Epithelial–Mesenchymal Transition</p>
Author(s) -
Huachen Song,
Xiaonan Tang,
Xiang Li,
Yufei Wang,
AnJun Deng,
Wenjie Wang,
HaiJing Zhang,
HaiLin Qin,
LiWei Wu
Publication year - 2020
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s262806
Subject(s) - epithelial–mesenchymal transition , mesenchymal stem cell , cancer research , in vivo , chemistry , western blot , carcinogenesis , cancer , metastasis , biology , pathology , medicine , biochemistry , microbiology and biotechnology , gene
Colitis-associated cancer (CAC) accounts for approximately 15% of IBD patient mortalities. However, currently available anti-CAC drugs possess many disadvantages including safety, specificity and side effects. Therefore, the development of novel anti-CAC compounds is imperative. HLJ2 was a monomeric compound synthesized by our institute and reported to have an effect on ulcer colitis.